Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001211652 | SCV001383202 | pathogenic | Metachromatic leukodystrophy | 2023-07-26 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the ARSA protein in which other variant(s) (p.Cys495Phe) have been determined to be pathogenic (PMID: 19021637). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. ClinVar contains an entry for this variant (Variation ID: 941799). This variant has not been reported in the literature in individuals affected with ARSA-related conditions. This variant is present in population databases (rs148352371, gnomAD 0.009%). This sequence change creates a premature translational stop signal (p.Glu483*) in the ARSA gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 27 amino acid(s) of the ARSA protein. |
Natera, |
RCV001211652 | SCV002081636 | likely pathogenic | Metachromatic leukodystrophy | 2021-10-06 | no assertion criteria provided | clinical testing |